Literature DB >> 17453170

[Prevention of osteoporosis--important for the urologist?].

G Lümmen1, H Rübben, T Schneider, H Sperling.   

Abstract

Osteoporosis is a systemic disease of the bones with increasing incidence in the elderly. Over the age of 50 years bone mineral density continuously decreases resulting in osteoporotic fracture. Osteoporosis is positively correlated with late-onset hypogonadism and increases under androgen deprivation therapy. The evaluation of osteoporosis should be done in cooperation with an endocrinologist. Measurement of bone mineral density is recommended before starting androgen deprivation therapy. Patients with fracture and/or decreased bone mineral density 2.5 or more standard deviations below normal peak bone mass of young men should be treated. The appropriate treatment is calcium and vitamin D substitution combined with oral or i.v. administration of bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453170     DOI: 10.1007/s00120-007-1349-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  29 in total

1.  Osteonecrosis of the jaw and bisphosphonates.

Authors:  Brian G M Durie; Michael Katz; John Crowley
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

2.  Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

Authors:  E S Kurland; F Cosman; D J McMahon; C J Rosen; R Lindsay; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

3.  Doctors and healthcare reform.

Authors:  S J Duckett
Journal:  Med J Aust       Date:  1997-08-18       Impact factor: 7.738

Review 4.  Treatment-related osteoporosis in men with prostate cancer.

Authors:  Matthew R Smith
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

5.  Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer.

Authors:  Douglas Scherr; W Reid Pitts; E Darracott Vaughn
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

6.  Alendronate for the treatment of osteoporosis in men.

Authors:  E Orwoll; M Ettinger; S Weiss; P Miller; D Kendler; J Graham; S Adami; K Weber; R Lorenc; P Pietschmann; K Vandormael; A Lombardi
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

7.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Authors:  M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

Review 8.  Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Authors:  Robert W Ross; Eric J Small
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

9.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 10.  Maintaining bone health in patients with prostate cancer.

Authors:  D Jane Holmes-Walker; Henry Woo; Howard Gurney; Viet T Do; David R Chipps
Journal:  Med J Aust       Date:  2006-02-20       Impact factor: 7.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.